Cargando…
Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection
Only limited data are available regarding the immunogenicity of the BNT162b2 mRNA vaccine in HIV-1(+) patients. Therefore, we investigated the humoral immune response after BNT162b2-mRNA vaccination or SARS-CoV-2 infection in HIV-1(+) patients on antiretroviral therapy compared to HIV-1-uninfected s...
Autores principales: | Schmidt, Katja G., Harrer, Ellen G., Tascilar, Koray, Kübel, Sabrina, El Kenz, Boutaina, Hartmann, Fabian, Simon, David, Schett, Georg, Nganou-Makamdop, Krystelle, Harrer, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952283/ https://www.ncbi.nlm.nih.gov/pubmed/35337058 http://dx.doi.org/10.3390/v14030651 |
Ejemplares similares
-
SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses
por: Schmidt, Katja G., et al.
Publicado: (2021) -
Ex Vivo Blockade of the PD-1 Pathway Improves Recall IFNγ Responses of HIV-Infected Persons on Antiretroviral Therapy
por: Fischhaber, Natalie, et al.
Publicado: (2023) -
Definition of a New HLA B*52-Restricted Rev CTL Epitope Targeted by an HIV-1-Infected Controller
por: El Kenz, Boutaina, et al.
Publicado: (2023) -
Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine
por: Schmidt, Katja G., et al.
Publicado: (2023) -
Humoral and Cellular Immune Responses to SARS–CoV‐2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion
por: Simon, David, et al.
Publicado: (2021)